Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2012 1
2016 1
2017 1
2018 1
2019 3
2020 3
2021 4
2022 7
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A. Venter WDF, et al. Among authors: akpomiemie g. Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1. Lancet HIV. 2020. PMID: 33010240 Clinical Trial.
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Bosch B, Akpomiemie G, Chandiwana N, Sokhela S, Hill A, McCann K, Qavi A, Mirchandani M, Venter WDF. Bosch B, et al. Among authors: akpomiemie g. Clin Infect Dis. 2023 Apr 17;76(8):1492-1495. doi: 10.1093/cid/ciac949. Clin Infect Dis. 2023. PMID: 36519389 Clinical Trial.
Risks of metabolic syndrome in the ADVANCE and NAMSAL trials.
Tovar Sanchez T, Mpoudi-Etame M, Kouanfack C, Delaporte E, Calmy A, Venter F, Sokhela S, Bosch B, Akpomiemie G, Tembo A, Pepperrell T, Simmons B, Casas CP, McCann K, Mirchandani M, Hill A. Tovar Sanchez T, et al. Among authors: akpomiemie g. Front Reprod Health. 2023 Sep 18;5:1133556. doi: 10.3389/frph.2023.1133556. eCollection 2023. Front Reprod Health. 2023. PMID: 37791109 Free PMC article.
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
Griesel R, Maartens G, Chirehwa M, Sokhela S, Akpomiemie G, Moorhouse M, Venter F, Sinxadi P. Griesel R, et al. Among authors: akpomiemie g. Clin Infect Dis. 2021 Dec 6;73(11):e3902-e3909. doi: 10.1093/cid/ciaa1073. Clin Infect Dis. 2021. PMID: 32960272 Free PMC article. Clinical Trial.
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P, Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill A. Venter WDF, et al. Among authors: akpomiemie g. N Engl J Med. 2019 Aug 29;381(9):803-815. doi: 10.1056/NEJMoa1902824. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31339677 Clinical Trial.
27 results